Alkalay A L, Mazkereth R, Santulli T, Pomerance J J
Division of Neonatology, Ahmanson Pediatric Center, Cedars-Sinai Medical Center, University of California, School of Medicine, Los Angeles.
Am J Perinatol. 1993 Jul;10(4):323-6. doi: 10.1055/s-2007-994752.
Increased risk of central venous line thrombosis in tiny premature infants occurs because the size of the catheter relative to the cross-sectional area of the vessel is large, decreased plasma levels of plasminogen and antithrombin III, and relative low flow of the infusate through the catheter, in comparison with larger infants. A potentially fatal complication of central venous catheters is an intracardiac thrombus. The yield of detecting right atrial thrombi by routine echocardiographic monitoring is very low. Persistent positive blood cultures in infants with central venous lines, in spite of appropriate antibiotic therapy, or signs of catheter occlusion, may increase the yield of echocardiographic detection of intracardiac thrombi. Surgical removal of intracardiac thrombi in infants weighing less than 1500 gm carries a high mortality rate because of the need to use cardiopulmonary bypass with total circulatory arrest and profound hypothermia during surgery. It is in these infants that thrombolysis with urokinase should be considered. A successful therapy with urokinase of a complete occlusion of the right pulmonary artery by an embolus originating from the right atrium is described in a premature infant. For thrombolysis, a loading dose of urokinase of 4400 U/kg followed by 4400 to 8800 U/kg/hr for a few days was used. The thrombolytic effect was manifested by decreased thrombus echogenicity followed by its disappearance, by increased fibrinogen split products, and by decreased plasma fibrinogen. Urokinase therapy may cause massive bleeding, dislodge an intracardiac thrombus causing obstruction of cardiac valves or main vessels or causing embolization to the pulmonary or systemic circulation.(ABSTRACT TRUNCATED AT 250 WORDS)
极小的早产儿发生中心静脉导管血栓形成的风险增加,原因在于与较大婴儿相比,导管尺寸相对于血管横截面积较大、血浆纤溶酶原和抗凝血酶III水平降低以及输注液通过导管的流量相对较低。中心静脉导管的一种潜在致命并发症是心内血栓。通过常规超声心动图监测检测右心房血栓的检出率非常低。尽管进行了适当的抗生素治疗,但中心静脉置管婴儿持续出现阳性血培养结果或出现导管阻塞迹象,可能会提高心内血栓的超声心动图检出率。体重小于1500克的婴儿手术切除心内血栓的死亡率很高,因为手术期间需要使用体外循环并完全停止循环以及深度低温。正是在这些婴儿中应考虑使用尿激酶进行溶栓治疗。一名早产儿描述了用尿激酶成功治疗由右心房栓子导致的右肺动脉完全阻塞的情况。对于溶栓治疗,使用了4400 U/kg的尿激酶负荷剂量,随后几天以4400至8800 U/kg/小时的剂量给药。溶栓效果表现为血栓回声性降低随后消失、纤维蛋白原降解产物增加以及血浆纤维蛋白原降低。尿激酶治疗可能会导致大量出血、使心内血栓脱落导致心脏瓣膜或主要血管阻塞或导致肺循环或体循环栓塞。(摘要截短至250字)